Merck Named a Top 50 Company for Diversity by DiversityInc


April 24, 2013 3:43 pm ET

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has been named a Top 50 company for diversity by DiversityInc for 2013. The list recognizes companies with 1,000 or more employees that consistently use diversity-management initiatives throughout their organizations.

Merck was ranked #12 on the list, up from #16 in 2012. In addition, the company was ranked #9 for Asian-Americans and #9 for Global Diversity.

“At Merck, we have a deep appreciation of the importance of having a workforce that reflects the diversity of our patients and customers around the world,” said Dottie Brienza, Chief Diversity Officer, Merck. “We believe that the unique and collective ideas and perspectives of our diverse talent allow us to develop innovative solutions in our continuing legacy to help the world be well.”

Merck provides employees with a number of programs and resources that promote and celebrate diversity. The company has nine Employee Resource Groups that represent women; African-Americans; Hispanics; Native Americans and indigenous people; Asian Americans; lesbian, gay, bisexual and transgender (LGBT) people; military veterans of all services and ranks; people of various religious faiths; and people who are differently abled. Merck also established the Business Insights Roundtable in 2012 to ensure that the company continues to harness the innovation and passion of colleagues from around the world to solve for customer and business needs. 

This is the eleventh year in a row that Merck has been named to DiversityInc’s Top 50 list.

About Merck

Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside of the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit and connect with us on Twitter, Facebook and YouTube

Merck forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.  

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2012 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (

Maria Tortoreto, 908-423-4598
Justin Holko, 908-423-5088

Unsubscribe from email alerts